Memorial Day! 45% Off Premium Subscription Claim Offer ⏰ 0d 00h 00m 00s

Arrowhead Research Earnings Calls

Q1 2025 Beat
$2.75 (4,683.33%)
Release date May 12, 2025
EPS estimate -$0.0600
EPS actual $2.75
EPS Surprise 4,683.33%
Revenue estimate 116.268M
Revenue actual 542.709M
Revenue Surprise 366.77%
Q4 2024 Missed
-$1.39 (-230.95%)
Release date Feb 10, 2025
EPS estimate -$0.420
EPS actual -$1.39
EPS Surprise -230.95%
Revenue estimate 19.05M
Revenue actual 2.5M
Revenue Surprise -86.88%
Q3 2024 Missed
-$1.38 (-31.43%)
Release date Nov 26, 2024
EPS estimate -$1.05
EPS actual -$1.38
EPS Surprise -31.43%
Revenue estimate 55.067M
Revenue actual 3.551M
Revenue Surprise -93.55%
Q2 2024 Missed
-$1.38 (-137.93%)
Release date Aug 08, 2024
EPS estimate -$0.580
EPS actual -$1.38
EPS Surprise -137.93%
Revenue estimate 69.67M
Revenue actual -

Last 4 Quarters for Arrowhead Research

Below you can see how ARWR performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.

Q2 2024 Missed
Release date Aug 08, 2024
Fiscal end date Jun 30, 2024
Price on release $25.85
EPS estimate -$0.580
EPS actual -$1.38
EPS surprise -137.93%
Date Price
Aug 02, 2024 $26.22
Aug 05, 2024 $25.08
Aug 06, 2024 $25.86
Aug 07, 2024 $25.00
Aug 08, 2024 $25.85
Aug 09, 2024 $23.41
Aug 12, 2024 $22.94
Aug 13, 2024 $22.86
Aug 14, 2024 $22.70
4 days before -1.41%
4 days after -12.19%
On release day -9.44%
Change in period -13.42%
Q3 2024 Missed
Release date Nov 26, 2024
Fiscal end date Sep 30, 2024
Price on release $21.05
EPS estimate -$1.05
EPS actual -$1.38
EPS surprise -31.43%
Date Price
Nov 20, 2024 $18.71
Nov 21, 2024 $18.28
Nov 22, 2024 $18.54
Nov 25, 2024 $18.79
Nov 26, 2024 $21.05
Nov 27, 2024 $26.15
Nov 29, 2024 $26.03
Dec 02, 2024 $26.34
Dec 03, 2024 $26.07
4 days before 12.51%
4 days after 23.85%
On release day 24.23%
Change in period 39.34%
Q4 2024 Missed
Release date Feb 10, 2025
Fiscal end date Dec 31, 2024
Price on release $19.92
EPS estimate -$0.420
EPS actual -$1.39
EPS surprise -230.95%
Date Price
Feb 04, 2025 $19.68
Feb 05, 2025 $20.27
Feb 06, 2025 $20.48
Feb 07, 2025 $20.24
Feb 10, 2025 $19.92
Feb 11, 2025 $18.89
Feb 12, 2025 $18.57
Feb 13, 2025 $19.11
Feb 14, 2025 $19.95
4 days before 1.22%
4 days after 0.151%
On release day -5.17%
Change in period 1.37%
Q1 2025 Beat
Release date May 12, 2025
Fiscal end date Mar 31, 2025
Price on release $13.97
EPS estimate -$0.0600
EPS actual $2.75
EPS surprise 4,683.33%
Date Price
May 06, 2025 $13.08
May 07, 2025 $13.06
May 08, 2025 $13.25
May 09, 2025 $13.03
May 12, 2025 $13.97
May 13, 2025 $15.28
May 14, 2025 $14.91
May 15, 2025 $15.34
May 16, 2025 $15.71
4 days before 6.80%
4 days after 12.46%
On release day 9.38%
Change in period 20.11%

Arrowhead Research Earnings Call Transcript Summary of Q1 2025

Key Investor Takeaways from Arrowhead's Earnings Call:

  • Sarepta Collaboration Details:
    • The license and collaboration agreement with Sarepta Therapeutics is finalized, delivering Arrowhead an upfront payment of $500 million within 10 days, along with $325 million received from Sarepta's purchase of Arrowhead stock.
    • Arrowhead can expect $250 million in annual installments and up to $300 million in near-term payments related to a Phase I/II study of ARO-DM1.
    • The total potential value of this collaboration exceeds $11 billion, including royalties on commercial sales and milestone payments.
  • Financial Position and Future Outlook:
    • Arrowhead is now funded into 2028, with cash and investments totaling approximately $552.9 million as of December 31, 2024. Post-Sarepta cash inflows will increase this balance to about $1.4 billion.
    • The company is focusing on partnering non-core assets to generate additional capital.
  • Clinical Development Highlights:
    • Plozasiran, a key drug for the treatment of familial chylomicronemia syndrome (FCS), is anticipated for FDA approval with a PDUFA action date of November 18, 2025. A launch could happen soon after regulatory approval.
    • The company views plozasiran as a $2 billion-$3 billion potential drug in the severe hypertriglyceridemia (SHTG) market.
    • Ongoing Phase III studies (SHASTA) are expected to be fully enrolled this year, leading to additional regulatory submissions in 2026.
    • Arrowhead's obesity-related programs, ARO-INHBE and ARO-ALK7, are in the early stages of clinical trials, with data anticipated later this year.
  • Strategic Developments:
    • Arrowhead aims to maintain ownership of certain leading drug candidates, including ARO-MAPT and ARO-SNCA, while exploring partnerships for other programs that are less core to its pipeline.
    • There’s a strategic focus on addressing the growing demand in the obesity and CNS (central nervous system) treatment markets as part of an expanding cardiometabolic pipeline.
  • Market Positioning and Competitors:
    • The management believes that both Arrowhead and Ionis, with their competing therapies, can help expand the market for triglyceride management, especially among undiagnosed patients.
    • Discussions on competition with alternative therapies and positioning are ongoing, with management emphasizing the differentiation of plozasiran's efficacy and dosing convenience.
  • Financial Performance:
    • Arrowhead reported a net loss of $173.1 million for Q4 2024. The operating expenses increased compared to the same quarter last year, driven by increased R&D activities.
    • Revenue for the quarter was low, related primarily to previous collaborations, but substantial incoming funds from the Sarepta agreement are expected in the coming periods.

Investors should closely monitor upcoming FDA decisions, clinical trial outcomes, and market acceptance as Arrowhead positions itself for growth in both the cardiometabolic space and its novel CNS pipeline.

Arrowhead Research Earnings History

Earnings Calendar

FAQ

When is the earnings report for ARWR?
Arrowhead Research Corporation (ARWR) has scheduled its earnings report for Aug 14, 2025 after the markets close.

What is the ARWR price-to-earnings (P/E) ratio?
ARWR P/E ratio as of May 23, 2025 (TTM) is -14.13.

What is the ARWR EPS forecast?
The forecasted EPS (Earnings Per Share) for Arrowhead Research Corporation (ARWR) for the first fiscal quarter 2025 is -$0.94.

What are Arrowhead Research Corporation's retained earnings?
On its balance sheet, Arrowhead Research Corporation reported retained earnings of $542.71 million for the latest quarter ending Mar 31, 2025.

What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.

Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.

What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
Click to get the best stock tips daily for free!
ABOUT ARROWHEAD RESEARCH CORPORATION
Arrowhead Research
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in P...
GOLDEN STAR
Ticker Change Signal Date
UAA
$5.84
14.55% May 09
HBM
$7.41
18.89% May 05
PODD
$257.01
25.04% May 02
GT
$9.14
19.80% Mar 21
O
ODD
$44.71
55.78% Mar 13

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE